NIH Cash Fuels eXoZymes’ Push Into Next‑Gen Cannabinoids
eXoZymes Inc (NASDAQ: EXOZ) picked up another non‑dilutive win and the stock responded, nudging higher after the company secured a new $2 million NIH grant to advance its cannabinoid analog platform. The award reinforces eXoZymes’ positioning as an AI‑driven enzyme shop that can use grant funding to push early drug‑discovery work without leaning solely on equity markets.
What eXoZymes just announced
eXoZymes received a Notice of Award from the National Institute of General Medical Sciences for a Phase IIB Small Business Innovation Research (SBIR) grant totaling $2,028,518. The NIH‑backed project will start on July 1, 2026 and support the company’s program to produce rare cannabinoids and engineer new cannabinoid analogs that could feed into future nutraceutical or pharmaceutical products.
The grant structure splits funding over two years: about $1,034,289 in the first budget period and $994,229 in the second, contingent on scientific progress and continued NIH funding availability. With this award, eXoZymes’ cumulative non‑dilutive funding climbs to roughly $19.7 million, giving the company added runway to develop its AI‑enhanced enzyme and cannabinoid toolkits.
Investor angle
For EXOZ holders, the headline move was modest — shares rose about 3.9% in after‑hours trading — but the grant matters more than the one‑day pop. NIH validation and non‑dilutive capital help de‑risk early discovery work, keep pressure off the balance sheet, and support a longer‑term story around rare cannabinoid manufacturing and analog design that could eventually translate into partnered or in‑house drug programs.
